Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Apr-30-22 | Apr-30-21 | Apr-30-20 | Apr-30-19 | Apr-30-18 | Apr-30-17 | Apr-30-16 | Apr-30-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Total revenues [+] | 49.1 | 41.0 | 32.1 | 27.1 | 20.2 | 15.4 | 11.2 | 8.9 |
| Services | | | | | | 15.4 | 11.2 | 8.9 |
| Revenue growth [+] | 19.7% | 27.8% | 18.7% | 33.7% | 31.3% | 37.8% | 26.2% | -23.3% |
| Personalized Oncology Solutions | | | | | | | 18.6% | -26.5% |
| Cost of goods sold | 23.6 | 21.4 | 17.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 25.5 | 19.6 | 15.1 | 27.1 | 20.2 | 15.4 | 11.2 | 8.9 |
| Gross margin | 51.9% | 47.7% | 47.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 15.5 | 12.0 | 10.9 | 7.7 | 6.6 | 8.2 | 8.6 | 9.6 |
| Sales and marketing | 6.4 | 5.5 | 4.2 | 3.1 | 2.6 | 3.3 | 3.4 | 4.3 |
| General and administrative | 9.1 | 6.5 | 6.6 | 4.7 | 4.1 | 5.0 | 5.2 | 5.3 |
| Research and development | 9.4 | 7.2 | 5.9 | 4.8 | 4.4 | 4.3 | 4.2 | 4.8 |
| Other operating expenses | | | | 14.3 | 10.6 | 9.7 | 8.7 | 7.6 |
| EBITDA [+] | 2.2 | 1.6 | -0.8 | 0.9 | -1.0 | -6.6 | -10.2 | -13.0 |
| EBITDA growth | 44.1% | -303.7% | -186.9% | -188.1% | -85.0% | -34.6% | -22.0% | 115.4% |
| EBITDA margin | 4.5% | 3.8% | -2.4% | 3.2% | -4.9% | -43.1% | -90.9% | -146.9% |
| Depreciation and amortization | 1.6 | 1.2 | 0.8 | 0.6 | 0.4 | 0.2 | 0.2 | 0.2 |
| EBIT [+] | 0.6 | 0.4 | -1.6 | 0.3 | -1.4 | -6.8 | -10.3 | -13.2 |
| EBIT growth | 65.8% | -123.1% | -687.4% | -119.9% | -80.1% | -34.0% | -22.1% | 111.5% |
| EBIT margin | 1.2% | 0.9% | -4.9% | 1.0% | -6.7% | -44.2% | -92.3% | -149.4% |
| Non-recurring items [+] | | | 0.3 | | | | | |
| Asset impairment | | | 0.3 | | | | | |
| Other income (expense), net [+] | 0.0 | 0.1 | 0.0 | 0.0 | -0.1 | -0.1 | 0.0 | 0.2 |
| Unrealized gain/loss on derivatives | | | | | | | | 1.0 |
| Other | 0.0 | 0.1 | 0.0 | 0.0 | -0.1 | -0.1 | 0.0 | -0.2 |
| Pre-tax income | 0.6 | 0.4 | -2.0 | 0.2 | -1.4 | -6.9 | -10.4 | -13.0 |
| Income taxes | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 |
| Tax rate | 6.0% | 17.2% | | 44.6% | | | | |
| Net income | 0.5 | 0.4 | -2.1 | 0.1 | -1.5 | -6.9 | -10.4 | -13.1 |
| Net margin | 1.1% | 0.9% | -6.5% | 0.5% | -7.3% | -44.8% | -93.4% | -148.3% |
| |
| Basic EPS [+] | $0.04 | $0.03 | ($0.18) | $0.01 | ($0.13) | ($0.65) | ($1.20) | ($2.20) |
| Growth | 50.7% | -115.6% | -1665.7% | -108.4% | -79.2% | -46.2% | -45.3% | 1882.0% |
| Diluted EPS [+] | $0.04 | $0.02 | ($0.18) | $0.01 | ($0.13) | ($0.65) | ($1.20) | ($2.05) |
| Growth | 55.8% | -114.1% | -2046.2% | -106.8% | -79.2% | -46.2% | -41.3% | 1746.6% |
| |
| Shares outstanding (basic) [+] | 13.2 | 13.1 | 11.8 | 11.3 | 11.0 | 10.7 | 8.7 | 6.0 |
| Growth | 0.4% | 10.9% | 4.4% | 3.2% | 2.9% | 22.9% | 45.3% | -91.0% |
| Shares outstanding (diluted) [+] | 14.2 | 14.6 | 11.8 | 14.1 | 11.0 | 10.7 | 8.7 | 6.4 |
| Growth | -2.8% | 23.1% | -16.0% | 28.3% | 2.9% | 22.9% | 35.3% | -90.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|